Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies.
Jonathan P CharlesAndrea VrionisArian MansurTrevor J MathiasJamil ShaikhAaron CinerYixing JiangNariman NezamiPublished in: Cancers (2023)
Liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, is increasing in incidence and mortality across the globe. An improved understanding of the complex tumor microenvironment has opened many therapeutic doors and led to the development of novel pharmaceuticals targeting cellular signaling pathways or immune checkpoints. These interventions have significantly improved tumor control rates and patient outcomes, both in clinical trials and in real-world practice. Interventional radiologists play an important role in the multidisciplinary team given their expertise in minimally invasive locoregional therapy, as the bulk of these tumors are usually in the liver. The aim of this review is to highlight the immunological therapeutic targets for primary liver cancers, the available immune-based approaches, and the contributions that interventional radiology can provide in the care of these patients.
Keyphrases
- clinical trial
- minimally invasive
- quality improvement
- healthcare
- palliative care
- artificial intelligence
- ejection fraction
- end stage renal disease
- signaling pathway
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- pain management
- mesenchymal stem cells
- epithelial mesenchymal transition
- patient reported outcomes
- cell proliferation
- peritoneal dialysis
- young adults
- patient reported
- double blind